

---

# **FDA Consolidation at the Federal Research Center at White Oak**

## **Supplemental Environmental Impact Statement**

**GSA**

National  
Capital  
Region



---

# One Campus – One FDA

## FDA Headquarters Consolidation:

- Provides high-tech infrastructure
- Brings FDA Headquarters staff together from 39 buildings in the Washington, DC metropolitan area
- Allows FDA to standardize and modernize processes
- Creates synergy to improve scientific rigor across FDA
- Strengthens ability to protect and promote public health



---

## FDA's Affect on Everyday Life

FDA regulates \$1 trillion worth of products or 25¢ of every dollar spent by American consumers

FDA touches the lives of every American by ensuring that:

- The food we eat safe
- Consumer products won't hurt us
- Medical devices and medicines are safe
- We are protected from radiation-emitting products
- Feed and drugs for pet and farm animals are safe
- Products are labeled truthfully



# Protecting the Homeland Against Bioterrorism

FDA is responsible for development, testing, and licensing of vaccines for bioterrorist pathogens including:

- Anthrax
- Smallpox
- Tularemia
- Plague
- Hemorrhagic fever

Vaccines are America's first defense against disease



---

# National and Global Preparedness

FDA plays a critical role in national and global preparedness to handle:

- Pandemic and annual influenza surges
- West Nile virus, SARS, dengue, and Chagas disease



# Safe and Effective Products

FDA's standards are vital to:

- Blood supply safety
- Speeding product availability and enhancing quality
- Enhancing gene and cell therapy safety and effectiveness



---

# Safe and Effective Products

FDA develops strategies to reduce threats, prevent attacks, and assist in recovery for:

- Food Safety
- Antimicrobial resistance
- Biosecurity
- Biotechnology



---

# FDA Consolidation at the Federal Research Center at White Oak


## FDA Centers

- Center for Drug Evaluation and Research (CDER)
- Center for Devices and Radiological Health (CDRH)
- Center for Biologics Evaluation and Research (CBER)
- Center for Veterinary Medicine (CVM)
- Office of the Commissioner (OC)
- Office of Regulatory Affairs (ORA)



# Site Map

FDA  
CONSOLIDATION



National  
Capital  
Region



# Existing FDA Headquarters Master Plan



National  
Capital  
Region



---

# History of FDA Headquarters Consolidation

Environmental Impact Statement completed in 1997

Included:

- 5,947 employees
- 2,111,421 gross square feet of laboratories, offices, and support facilities

GSA issued a Record of Decision in July 1997

Construction began in October 2000



---

# History of FDA Headquarters Consolidation

Supplemental Environmental Impact Statement completed in 2005

- Eastern access road through the site
- Expanded buildings to accommodate increase in employees
- Changed the location of the Day Care Center
- The approved number of employees is 7,719



---

# Proposed Changes to the FDA Headquarters Consolidation

H.R. 3580 – FDA Amendments Act of 2007

Prescription Drug User Fee Act (PDUFA) and the  
Medical Device User Fee Modernization Act (MDUFMA)  
were reauthorized and expanded

Best Pharmaceuticals for Children Act (BPCA) and the  
Pediatric Research Equity Act (PREA) were  
reauthorized



---

# Proposed Changes to the FDA Headquarters Consolidation


Increase FDA employees at the FRC by 1,170

Expand buildings to accommodate increase in  
employees

Construct infrastructure  
improvements



# 2008 Potential FDA Development Plan



---

# Supplemental EIS

Will be prepared in accordance with the National Environmental Policy Act (NEPA) of 1969

Will inform the public and assess impacts to the human environment including natural, social, and cultural resources from a range of alternatives

Findings in the SEIS will be used in GSA's decision making process



Notice of Intent for Supplemental EIS, March 7, 2008

Scoping Activities to Identify Issues and Alternatives  
(30-Day Comment Period)

*Current Step in Process*



Notice of Intent for Supplemental EIS, March 7, 2008

Scoping Activities to Identify Issues and Alternatives  
(30-Day Comment Period)

*Current Step in Process*

Define Proposed Action Alternatives

Assess Impacts of Proposed Action



Notice of Intent for Supplemental EIS, March 7, 2008

Scoping Activities to Identify Issues and Alternatives  
(30-Day Comment Period)

*Current Step in Process*

Define Proposed Action Alternatives

Assess Impacts of Proposed Action

Publish Draft Supplemental EIS

45-Day Public Review of Draft and Public Hearing



Notice of Intent for Supplemental EIS, March 7, 2008

Scoping Activities to Identify Issues and Alternatives  
(30-Day Comment Period)

*Current Step in Process*

Define Proposed Action Alternatives

Assess Impacts of Proposed Action

Publish Draft Supplemental EIS

45-Day Public Review of Draft and Public Hearing

Publish Final Supplemental EIS Which Addresses  
Comments Received on Draft

30-Day Review Period



Notice of Intent for Supplemental EIS, March 7, 2008

Scoping Activities to Identify Issues and Alternatives  
(30-Day Comment Period)

*Current Step in Process*

Define Proposed Action Alternatives

Assess Impacts of Proposed Action

Publish Draft Supplemental EIS

45-Day Public Review of Draft and Public Hearing

Publish Final Supplemental EIS Which Addresses  
Comments Received on Draft

30-Day Review Period

Issue Record of Decision

Implement Decision (With Mitigation and/or  
Monitoring Where Specified in EIS/ROD)

GSA

National  
Capital  
Region



---

# Providing Scoping Comments

Comment forms are available at the sign-in table

Written comments must be postmarked by April 7, 2008

Tape recorders are available by the front entrance to record comments

Comments can be mailed in or emailed to:

**[Suzanne.Hill@gsa.gov](mailto:Suzanne.Hill@gsa.gov)**



---

# Thank You

GSA

National  
Capital  
Region

